다발성 골수종

96개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved96 programs
CGTLimited DatastaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedRefractoryMultipleMyelom+1
Trials 1Status Recruiting
CGTLimited DatastaleWuerzburg University HospitalPhase 2

SLAMF7 CAR-T (SLAMF7 CAR-T)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleOslo University HospitalPhase 3

daratumumab (Darzalex, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Oslo
Trials 1Status Recruiting
CGTLimited DatastaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleDavid WaldPhase 1

UF-KURE-BCMA CAR T-cells (UF-KURE-BCMA CAR T-cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
ADCLimited DatastaleGlaxoSmithKlinePhase 2

Unconjugated belantamab antibody (Unconjugated belantamab antibody)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GlaxoSmithKline
Trials 1Status Recruiting
ADCLimited DatastaleGlaxoSmithKlinePhase 2

belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GlaxoSmithKline
Trials 1Status Recruiting
CGTLimited DatastaleBioray LaboratoriesPhase 1

Universal BCMA-CD19 CART (Universal BCMA-CD19 CART)

Autoimmune Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastalePaula C. & Rodger O. Riney Bloo…Phase 1

WS-CART-CS1 (WS-CART-CS1)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology & Blood…Preclinical

anti-BCMA/GPRC5D bispecific CAR-T (anti-BCMA/GPRC5D bispecific CAR-T)

Extramedullary Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastalePeng LiuPhase 1

anti-CD19/BCMA CAR-T cells (anti-CD19/BCMA CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Progression · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleRui Therapeutics Co., LtdPhase 1

anti-CD19/BCMA U CAR T (anti-CD19/BCMA U CAR T)

Relapsed/Refractory Immune Nephropathy; Relapsed/Refractory Immune-mediated Kidney Disease · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleGilead SciencesPhase 2

the doxorubicin conjugate of milatuzumab (hLL1-DOX, hLL1-DOX (the doxorubicin conjugate of milatuzumab))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#Gilead
Trials 1Status Discontinued

5 / 5 pages

← PreviousNext →